---
id: "entity-openevidence"
type: "entity"
entityType: "product"
canonicalName: "OpenEvidence"
aliases: []
source_timestamps: ["§ Intro", "§ The 4C Framework for Building Generative Readiness"]
tags: ["healthcare-ai", "clinical-decision-support"]
related: ["claim-openevidence-scale", "entity-gsk"]
sources: ["geo"]
sourceVaultSlug: "hbr-seg-geo"
originDay: 3
articleStem: "hbr-tier1-01-gen-ai-b2b-buying"
sourceUrl: "https://hbr.org/2026/06/how-gen-ai-is-disrupting-b2b-buying-decisions"
sourceTitle: "How Gen AI is Disrupting B2B Buying Decisions"
---
# OpenEvidence

**OpenEvidence** is a clinical decision-support AI assistant designed for physicians, surfacing evidence-based recommendations at the point of care by integrating medical literature and guidelines. It originated at **Brown University** and was spun out to commercial use.

**Role in the source:** It is the opening proof point that AI-mediated professional decision-making is durable, not experimental — see [[claim-openevidence-scale]] (source-reported: used daily by >40% of U.S. physicians; >20M queries in January 2026, up sevenfold from ~2.6M in December 2024). [[entity-gsk]] engaged with OpenEvidence to understand how pharma publication standards must evolve for AI ([[quote-pharma-publication-standards]]).

**Canonical context (enrichment):** Existence and positioning as a clinical decision-support AI are well supported; the specific penetration and query-volume figures are vendor-reported and not independently verified.